How many insider trades does FilingIQ track for IMTX?

FilingIQ tracks 9 Form 4 insider transactions for IMTX (Immatics N.V.), covering filings from Jun 16, 2026 onwards. 9 of those were filed in the last 90 days.

Are IMTX insiders net buyers or net sellers?

Across the full Form 4 history for IMTX, 0 transactions (0%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does IMTX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is IMTX in?

Immatics N.V. (IMTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.34B.

IMTX insider trading

NasdaqCM Healthcare

Immatics N.V. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

0% / 0%

Market cap

$1.34B

About Immatics N.V.

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Company website: www.immatics.com

IMTX insider activity at a glance

FilingIQ has scored 9 insider transactions for IMTX since Jun 16, 2026. The most recent filing in our index is dated Jun 16, 2026.

Across the full history, 0 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

View live IMTX trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,204

UNITED THERAPEUTICS Corp

APLS 275

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

GH 159

Guardant Health, Inc.

First Tracks Biotherapeutics, Inc.

KALV 133

KalVista Pharmaceuticals, Inc.

Frequently asked

How many insider trades does FilingIQ track for IMTX?: FilingIQ tracks 9 Form 4 insider transactions for IMTX (Immatics N.V.), covering filings from Jun 16, 2026 onwards. 9 of those were filed in the last 90 days.
Are IMTX insiders net buyers or net sellers?: Across the full Form 4 history for IMTX, 0 transactions (0%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does IMTX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is IMTX in?: Immatics N.V. (IMTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.34B.

Methodology & sources

Every IMTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.